Carbapenem-Resistant Enterobacteriaceae (CRE) - ACPHD
Carbapenem-Resistant Enterobacteriaceae (CRE) are untreatable or difficult to treat bacteria that are resistant to carbapenem antibiotics and nearly all available antibiotics. They can cause serious illness and death; bloodstream infections are fatal in 40% -50% of cases. CRE was designated by the CDC in 2013 as one of the three most urgent drug resistant threats in the United States. An estimated 9,000 CRE infections cause 600 deaths yearly in the U.S.. Risk factors for CRE colonization or infection include open wounds, presence of indwelling devices (such as endotracheal tubes, feeding tubes, and catheters), multiple medical problems, and high antimicrobial use. CRE are easily spread between infected or colonized patients by health care workers and equipment, unless rigorous infection prevention precautions are taken. Cases and outbreaks of CRE have been increasingly recognized in recent years in Northern California, including Alameda County. In June 2017, the Alameda ...http://acphd.org/cre.aspx
Provider Role in Transmission of Carbapenem-Resistant Enterobacteriaceae | Infection Control & Hospital Epidemiology |...
Provider Role in Transmission of Carbapenem-Resistant Enterobacteriaceae - Volume 38 Issue 11 - Marika E. Grabowski, Hyojung Kang, Kristen M. Wells, Costi D. Sifri, Amy J. Mathers, Jennifer M. Lobohttps://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/provider-role-in-transmission-of-carbapenemresistant-enterobacteriaceae/8F4709AAF405D7AD6A68960229ABB106
Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE) - November 2015 Update CRE Toolkit | HAI | CDC
Carbapenem-resistant Enterobacteriaceae (CRE) are a serious threat to public health. Infections with CRE are difficult, and in some cases impossible, to treat and have been associated with mortality rates up to 50%(1). Due to the movement of patients throughout the healthcare system, if CRE are a problem in one facility, then typically they are a problem in other facilities in the region as well. To help protect patients and prevent transmission, CDC has updated 2012 CRE toolkit; this document will continue to be updated as new information becomes available.. ...https://www.cdc.gov/hai/organisms/cre/cre-toolkit/index.html
Successful management of an outbreak due to carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit. |...
PubMedID: 24985124 | Successful management of an outbreak due to carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit. | European journal of pediatrics | 7/2/2014https://www.docphin.com/research/article-detail/13775114/PubMedID-24985124/Successful-management-of-an-outbreak-due-to-carbapenem-resistant-Acinetobacter-baumannii-in-a-neonatal-intensive-care-unit
Molecular genetic analysis of cephalosporinase production and its role in beta-lactam resistance in clinical isolates of...
Two strains of Enterobacter cloacae were isolated from a patient before (strain MHN1) and during (strain MHN2) treatment with moxalactam and gentamicin. Strain MHN1 exhibited inducible ampC cephalosporinase production. In contrast, strain MHN2 expressed the enzyme constitutively at a 3,000-fold higher level. With the Escherichia coli ampC gene as a hybridization probe it was shown that the genomic arrangement of the ampC region was the same in both strains. To gain more insight into regulatory phenomena, the ampC genes were cloned, and their expression was studied in E. coli K-12. The ampC gene from MHN1 behaved normally and conferred inducible beta-lactam resistance. A regulatory region of at least 800 base pairs involved in controlling repression-induction was located immediately upstream of ampC. Surprisingly, when present in E. coli the ampC gene from MHN2 no longer overproduced the cephalosporinase, and ...https://infoscience.epfl.ch/record/151362
Epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an intensive care unit with no single rooms |...
Despite the unfavorable double-room configuration of our ICU, the 4.1% rate of ESBL acquisition was much lower than the 13% reported by Razazi et al. in a 24-bed ICU with eight single rooms but without any protocol of contact precautions for ESBL carriers . It is close to that reported by Alves et al. in an ICU with only single rooms, in which contact precautions were also applied . Unlike Barbier et al., who reported that half of the ESBL carriers acquired their ESBL during their ICU stay , and Gardam et al., who reported that ESBL acquisition accounted for two-thirds of ESBL carriage in the ICU , ESBL acquisition accounted for only 12.7% of all ESBL carriage in our study, confirming that ESBL carriage is mostly imported, whereas high-level cephalosporinase (HL-Case) is mostly acquired, in the ICU . In multivariate analysis, the severity (SAPS II) at admission was the only factor identified to be associated with the acquired carriage of ESBL, while some authors have ...https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-017-0295-0
Go to CRE.
What are carbapenem-resistant Enterobacteriaceae (CRE)? Enterobacteriaceae are a group of bacteria normally found in the human gut. Common types include E. coli and Klebsiella species. Carbapenems are a class of antibiotics that were developed to treat bacteria that are resistant to other drugs. Due to the overuse of these antibiotics, some types of Enterobacteriaceae have developed resistance to carbapenems; these bacteria are called carbapenem-resistant Enterobacteriaceae (CRE).. Who gets CRE? Healthy people usually do not get CRE infections. In healthcare settings, CRE infections may occur among patients who are receiving treatment for other conditions. Patients whose care requires devices like ventilators (breathing machines), urinary (bladder) catheters, or intravenous (vein) catheters, and patients who are taking long courses of certain antibiotics are most at risk for CRE infections.. How are CRE spread? CRE can be transmitted via ...http://www.vdh.virginia.gov/epidemiology/epidemiology-fact-sheets/carbapenem-resistant-enterobacteriaceae-cre/
Diversity of aminoglycoside modifying enzymes among carbapenem-resistant Klebsiella pneumoniae isolates and their impact on...
R Almaghrabi, CJ Clancy, Y Doi, R Shields, E Press, L Chen, B Kreiswirth, MH Nguyen. ICAAC 2014, Poster # C-1372. Download poster as PDF ...http://www.achaogen.com/media-all/2016/4/26/diversity-of-aminoglycoside-modifying-enzymes-among-carbapenem-resistant-klebsiella-pneumoniae-isolates-and-their-impact-on-activity-of-old-and-next-generation-aminoglycosides
carbapenem-resistant Enterobacteriaceae (CRE)
It was a week into my elderly patient's hospital admission when he began to have fever and profuse diarrhea, some 10-12 bowel movement a day. The diagnosis was not hard to make: a stool test showed he had C difficile. Another patient, a thin women in her late 40s who had become paraplegic after a […]. ...https://www.mjainmd.com/blog/tag/carbapenem-resistant-enterobacteriaceae-cre/
GeneWEAVE Presents Data for Smarticles™ Assay Targeted Towards Carbapenem-Resistant Enterobacteriaceae (CRE)
(PRWEB) May 15, 2015 -- GeneWEAVE, Inc.,a clinical diagnostics company addressing multi-drug-resistant organisms (MDRO), announced that initial data presentedhttp://www.prweb.com/releases/2015/05/prweb12725554.htm
Novel Mechanisms of Beta-Lactam Resistance in Staph Aureus | Global Research Projects
have discovered a novel mechanism of resistance to ?-lactams that is independent of penicillinase and the low affinity penicillin bindin protein (PBP), PBP2a, the two known mechanisms of ?-lactam resistance in Staphylococcus aureus. This new type of resistance was identified during experiments in which methicillin- susceptible S. aureus strains were passaged in the presence of each of the two so-called "fifth generation" anti-MRSA cephalosporins, ceftobiprole and ceftaroline. Whole genome sequencing of a ceftobiprole- passage mutant revealed mutations in genes encoding PBP4, a non-essential, low-molecular weight PBP; GdpP, a putative signaling protein; and AcrB, a putative transporter. Ceftaroline also selected for PBP4 and GdpP mutants, but not AcrB mutants, indicating the primary importance of the former two proteins. We hypothesize 1) that a gain of transpeptidase ...http://globalprojects.ucsf.edu/project/novel-mechanisms-beta-lactam-resistance-staph-aureus-0
Detection of extended-spectrum beta-lactamase in Pseudomonas aeruginosa.
Abstract PURPOSE: The present study was designed to detect the extended-spectrum beta-lactamase (ESBL) production in Pseudomonas aeruginosa and to evaluate the susceptibility patte..https://www.omicsonline.org/references/detection-of-extendedspectrum-betalactamase-in-pseudomonas-aeruginosa-558298.html
Superbug Infections: a Challenge to Healthcare Professionals
As patients move from different care settings and facilities, unknowingly spreading healthcare-associated infections, antibiotic-resistant superbugs like carbapenem-resistant Enterobacteriaceae (CRE) present a challenge to healthcare professionals.http://www.medindia.net/news/superbug-infections-a-challenge-to-healthcare-professionals-121838-1.htm
A stealthy superbug appears to be spreading in U.S. hospitals, study finds - The PBS NewsHour - WNYC
On the right plate, carbapenem-resistant Enterobacteriaceae is able to grow even in the presence of antibiotics. Photo by CDC A ...http://www.wnyc.org/story/a-stealthy-superbug-appears-to-be-spreading-in-us-hospitals-study-finds/
CRE Tops List of Scary Superbugs - ABC News
A new superbug is on the rise in U.S. hospitals, according to the U.S. Centers for Disease Control and Prevention. The germ, dubbed CRE for carbapenem-resistant Enterobacteriaceae, evades most if not all antibiotics, making it virtually untreatable.https://abcnews.go.com/Health/cre-tops-list-scary-superbugs/story?id=18666434
The Tough Fight Against the CRE Bacterium
Besides the constant care of patients, healthcare facilities have one more thing on their hands: the CRE (carbapenem-resistant Enterobacteriaceae) bacteria. This lethal enemy is unfortunately growing to be very common in intensive care settings to the point that there is an alert rising due to this.http://www.discountmedicalsupplies.com/doctors/health-news-doctors-blog/tough-fight-against-bacterium
iAH Search interface 2.4 - Results of the search |page 1|
Brink, Adrian et al. The spread of carbapenem-resistant Enterobacteriaceae in South Africa: Risk factors for acquisition and prevention. SAMJ, S. Afr. med. j., July 2012, vol.102, no.7, p.599-601. ISSN 0256- ...http://www.scielo.org.za/cgi-bin/wxis.exe/iah/?IsisScript=iah/iah.xis&base=article%5Edlibrary&format=iso.pft&lang=i&nextAction=lnk&indexSearch=AU&exprSearch=VAN+GREUNE,+JOHAN
Healthcare: Better use of antibiotics will help reduce spread of drug-resistant 'superbugs,' state health official says -...
After reports that a dangerous drug-resistant bacterium, carbapenem-resistant Klebsiella pneumoniae, or CRKP, had spread to at least 356 patients in Southern California last year, Times staff writerhttp://articles.latimes.com/2011/mar/28/local/la-me-infection-20110329
Several questions on evolution, and mutation (rate)
James Foster (foster at cs.uidaho.edu) wrote: ,Ahhh...gotcha. That is indeed an interesting question. I'm not sure ,what the answer is. I know that many new functions are co-opted from ,similar functions (I think the classical example is some enzyme ,beginning with the letter l...but can't remember right now). But that ,begs the question of where the co-opted behaviors came from. True, and I think also the important issue is how this new function arose from a similar function. The evolution, and natural selection, of classes of beta-lactamases are the examples I know. While we haven't observed it, the early beta-lactamases are hypothesised to have arisen from cell-wall enzymes and the bacteria were facing an enemy in nature (beta-lactams in fungi). Today, we have artificial beta-lactams that are not seen anywhere in nature, yet there are bacteria resistant to it. One ...http://www.bio.net/bionet/mm/microbio/1996-September/006664.html
POEMs: Beta-Lactam Not as Effective as Beta-Lactam Plus Macrolide for Treating CAP in the Hospital - American Family Physician
In this noninferiority trial, monotherapy with a beta-lactam was not as effective as combination therapy with a beta-lactam and a macrolide for achieving clinical stability in seven days for hospitalized patients with moderately severe CAP.http://www.aafp.org/afp/2015/0515/p720.html
An evaluation of the Idexx SNAP test for detecting beta-Lactam antibiotics in raw milk [enzyme linked receptor-binding assay]
Publisher : International Dairy Federation All titles : ' An evaluation of the Idexx SNAP test for detecting beta-Lactam antibiotics in raw milk [enzyme linked receptor-binding assay] ' ...http://agris.fao.org/agris-search/search.do?recordID=BE9600651
A Mechanism-Based Approach to Metallo-beta-Lactamase Inhibition - Robert Bonomo
The global dissemination of carbapenem-resistant Gram-negative pathogens is a significant source of morbidity and mortality. Carbapenemases, or carbapenem-hydro...http://grantome.com/grant/NIH/R01-AI100560-01
A Mechanism-Based Approach to Metallo-beta-Lactamase Inhibition - Robert Bonomo
The global dissemination of carbapenem-resistant Gram-negative pathogens is a significant source of morbidity and mortality. Carbapenemases, or carbapenem-hydro...http://grantome.com/grant/NIH/R01-AI100560-02
RCSB PDB for 1IYS
1IYS: Crystal Structure of Extended-Spectrum beta-Lactamase Toho-1: Insights into the Molecular Mechanism for Catalytic Reaction and Substrate Specificity Expansionhttp://www.rcsb.org/pdb/explore/images.do?structureId=1IYS
Publikācijas - Latvijas Organiskās sintēzes institūts
Veinberg G.; Shestakova I.; Bokaldere R.; Dikovskaya K.; Grigan N.; Musel D.; Vorona M.; Kanepe I.; Domracheva I.; Zharkova O.; Mežapuķe R.; Kalvinsh I.; Lukevics E. Cytotoxic properties of beta-lactam antibiotics structural analogs. Abstr., Baltijas valstu onkologu un radiologu 2. kongr. = 2nd Baltic congr. of oncology and radiology; 10.-12. sept.: Rīga, Latvija, 1998; 173 ...http://www.osi.lv/publikacijas/?op&gads=1998&pg=1